Benjamin Dizier

800 total citations
8 papers, 373 citations indexed

About

Benjamin Dizier is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Benjamin Dizier has authored 8 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Benjamin Dizier's work include Immunotherapy and Immune Responses (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and vaccines and immunoinformatics approaches (2 papers). Benjamin Dizier is often cited by papers focused on Immunotherapy and Immune Responses (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and vaccines and immunoinformatics approaches (2 papers). Benjamin Dizier collaborates with scholars based in Belgium, United States and Switzerland. Benjamin Dizier's co-authors include Bart Spiessens, Fernando Ulloa‐Montoya, Jamila Louahed, Johan Vansteenkiste, Frédéric Lehmann, Olivier Gruselle, Vincent Brichard, Alexander M.M. Eggermont, Wim H.J. Kruit and Stefan Suciu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Biometrics.

In The Last Decade

Benjamin Dizier

7 papers receiving 370 citations

Peers

Countries citing papers authored by Benjamin Dizier

Since Specialization

Citations

This map shows the geographic impact of Benjamin Dizier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Dizier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Dizier more than expected).

Fields of papers citing papers by Benjamin Dizier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Dizier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Dizier. The network helps show where Benjamin Dizier may publish in the future.

Co-authorship network of co-authors of Benjamin Dizier

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Dizier. A scholar is included among the top collaborators of Benjamin Dizier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Dizier. Benjamin Dizier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study* 2021 ·British Journal of Dermatology ·Ruth Oliver, James G. Krueger, Sophie Glatt, Pavan Vajjah, (unknown), Matthew Page, Hannah B Edwards, Sandra Garcet, Xuan Li, Benjamin Dizier, (unknown), Mark Watling, (unknown), Dominique Baeten, Lucian Ionescu, Stevan Shaw	32
2	A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Benjamin Dizier, Andrea Callegaro, Muriel Debois, Brigitte Dréno, Peter Hersey, Helen Gogas, John M. Kirkwood, Johan Vansteenkiste, Lecia V. Sequist, Djordje Atanackovic, Jelle J. Goeman, Hans C. van Houwelingen, Susana Alicia Salceda, (unknown), Patrick Therasse, C. Debruyne, Bart Spiessens, Vincent Brichard, Jamila Louahed, Fernando Ulloa‐Montoya	13
3	Testing interaction between treatment and high‐dimensional covariates in randomized clinical trials 2016 ·Biometrical Journal ·Andrea Callegaro, Bart Spiessens, Benjamin Dizier, (unknown), Hans C. van Houwelingen	3
4	A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative Controlled Clinical Studies 2015 ·Biometrics ·Junlong Li, Lihui Zhao, Lü Tian, Tianxi Cai, Brian Claggett, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Fernando Ulloa‐Montoya, L. J. Wei	31
5	Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy 2013 ·Journal of Clinical Oncology ·Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier, Olivier Gruselle, Bart Spiessens, Frédéric Lehmann, Stefan Suciu, Wim H.J. Kruit, Alexander M.M. Eggermont, Johan Vansteenkiste, Vincent Brichard	290
6	Clinical Activity Following the Administration of the MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Both the Melanoma and NSCLC is Associated With Similar Predictive Biomarkers Present Prior Treatment 2009 ·Frédéric Lehmann, Fernando Ulloa‐Montoya, Olivier Gruselle, Benjamin Dizier, Jamila Louahed, Johan Vansteenkiste, Alan Spatz, (unknown), (unknown)	2
7	Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment 2009 ·Molecular Cancer Therapeutics ·Jamila Louahed, Frédéric Lehmann, Fernando Ulloa‐Montoya, Olivier Gruselle, Benjamin Dizier, Johan Vansteenkiste, Wim H.J. Kruit, Vincent Brichard	0
8	GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC) 2008 ·Annals of Oncology ·J Jassem, Johan Vansteenkiste, M. Zieliński, Jubrail Dahabreh, A. Linder, (unknown), Benjamin Dizier, P. Therasse, Jamila Louahed, Vincent Brichard	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact